(Q45195142)

10 December 2017

title

Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy (English)

1 reference

10 December 2017

1 reference

Myoung Kuk Jang

1

1 reference

10 December 2017

Young-Hwa Chung

2

1 reference

10 December 2017

Min Hee Choi

3

1 reference

10 December 2017

Jeong A Kim

4

1 reference

10 December 2017

Soo Hyung Ryu

5

1 reference

10 December 2017

Jung Woo Shin

6

1 reference

10 December 2017

In Sook Kim

7

1 reference

10 December 2017

Neung Hwa Park

8

1 reference

10 December 2017

Han Chu Lee

9

1 reference

10 December 2017

Yung Sang Lee

10

1 reference

10 December 2017

Dong Jin Suh

11

1 reference

10 December 2017

publication date

1 December 2004

1 reference

Journal of Gastroenterology and Hepatology

10 December 2017

published in

1 reference

10 December 2017

volume

19

1 reference

10 December 2017

issue

12

1 reference

10 December 2017

page(s)

1363-1368

1 reference

Viral dynamics in hepatitis B virus infection

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Dynamics of hepatitis B virus infection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Combination therapy for hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2004.03464.X

10.1111/J.1440-1746.2004.03464.X

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference